Literature DB >> 24752732

Commentary: demonstrating cost-effectiveness in pediatric psychology.

Meghan E McGrady1.   

Abstract

OBJECTIVE: Changes in the health care system and payment plans will likely require pediatric psychologists to illustrate the impact of their services. Cost-effectiveness analyses are one method of demonstrating the potential economic benefits of our services but are rarely used by pediatric psychologists.
METHOD: A hypothetical cost-effectiveness analysis was conducted, comparing the costs and outcomes between a behavioral adherence intervention and no intervention for youth with acute lymphoblastic leukemia.
RESULTS: Results illustrate how pediatric psychologists can use cost-effectiveness analyses to demonstrate the economic impact of their work.
CONCLUSIONS: Efforts to conduct economic analyses could allow pediatric psychologists to advocate for their services. Implications and future directions are discussed.
© The Author 2014. Published by Oxford University Press on behalf of the Society of Pediatric Psychology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adherence; health policy; professional and training issues

Mesh:

Year:  2014        PMID: 24752732      PMCID: PMC4061600          DOI: 10.1093/jpepsy/jsu019

Source DB:  PubMed          Journal:  J Pediatr Psychol        ISSN: 0146-8693


  31 in total

Review 1.  Interventions for preventing obesity in children.

Authors:  Elizabeth Waters; Andrea de Silva-Sanigorski; Belinda J Hall; Tamara Brown; Karen J Campbell; Yang Gao; Rebecca Armstrong; Lauren Prosser; Carolyn D Summerbell
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  Commentary: Healthcare reform and psychology's workforce: preparing for the future of pediatric psychology.

Authors:  Ronald H Rozensky; David M Janicke
Journal:  J Pediatr Psychol       Date:  2012-01-18

Review 3.  The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.

Authors:  Richard H Chapman; Stacey L Kowal; Spencer B Cherry; Cheryl P Ferrufino; Craig S Roberts; Linda Chen
Journal:  Value Health       Date:  2010 Sep-Oct       Impact factor: 5.725

4.  Health care reform and cost control.

Authors:  Peter R Orszag; Ezekiel J Emanuel
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

5.  The CE plane: a graphic representation of cost-effectiveness.

Authors:  W C Black
Journal:  Med Decis Making       Date:  1990 Jul-Sep       Impact factor: 2.583

Review 6.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  The efficacy of adherence interventions for chronically ill children: a meta-analytic review.

Authors:  Montserrat M Graves; Michael C Roberts; Michael Rapoff; Amanda Boyer
Journal:  J Pediatr Psychol       Date:  2009-08-26

8.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

9.  Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?

Authors:  Wendy J Ungar
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

10.  Psychology in primary health care: effects of brief targeted therapy on children's medical care utilization.

Authors:  J W Finney; A W Riley; M F Cataldo
Journal:  J Pediatr Psychol       Date:  1991-08
View more
  1 in total

1.  A multimodal day treatment program for multi-problem young adults: study protocol for a randomized controlled trial.

Authors:  Marie-Jolette A Luijks; Floor Bevaart; Josjan Zijlmans; Laura van Duin; Reshmi Marhe; Theo A H Doreleijers; Henning Tiemeier; Jessica J Asscher; Arne Popma
Journal:  Trials       Date:  2017-05-19       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.